ARID1A and cancer: Together, these findings suggest a model wherein CRCs with ARID1A mutations have a higher TMB, which leads to the recruitment of PD‐L1‐expressing immune cells (especially macrophages) to the invasive front, enabling the cancer cells to escape immune response.